Skip to main content
. 2010 Apr 27;2(4):128–136. doi: 10.4240/wjgs.v2.i4.128

Table 1.

Summary of therapeutic results of 6 large series cohort studies with percutaneous RFA alone

Year Author PatientNo. Size (cm)1 FU (mo)2 LTP (%)3 New recur (%)4 Major Cx (%)5 Overall survival (%)
Median survival(mo) Evidence6
1 yr 3 yr 5 yr
2005 Lencioni et al[13] 206 < 5 24 10 49 2.0 97 67 41 57 2
2005 Tateishi et al[14] 319 < 5 28 8.7 60 4.0 95 78 54 NA 2
2005 Chen et al[15] 256 < 8 2-69 NA NA 2.4 83 67 41 NA 2
2007 Choi et al[16] 570 < 5 30 11.8 52 1.9 95 70 58 77 2
2008 Livraghi et al[17] 216 < 2 31 0.9 NA 1.8 NA 76 55 NA 2
2009 N'Kontchou et al[18] 235 < 5 27 11.5 42 0.9 NA 60 40 48

RFA: Radiofrequency ablation;

1

Maximum diameter of tumor;

2

Mean follow-up period;

3

Rate of local tumor progression;

4

Rate of new recurrence including intrahepatic remote and extrahepatic metastasis;

5

Rate of major complications requiring additional hospitalization or therapeutic procedure;

6

Level of evidence.